8 Amendments of Maria GRAPINI related to 2023/2179(DEC)
Amendment 2 #
Proposal for a decision 1
Paragraph 3
Paragraph 3
3. Instructs its President to forward this decision and the resolution forming an integral part of it to the InterimActing Executive Director of the Innovative Health Initiative Joint Undertaking, the Council, the Commission and the Court of Auditors, and to arrange for their publication in the Official Journal of the European Union (L series).;
Amendment 3 #
Motion for a resolution
Recital C
Recital C
C. whereas, to increase transparency, the Joint Undertaking should disclose in its annual accounts, relevant information regarding members’ contributions at programme level; whereas, for each programme under which they operate, the Joint Undertaking should present per member category up to the year-end, all relevant information including the legal contribution targets set for the respective programme, the volume of contributions received, and the volume of legal commitments; suggests that the Joint Undertaking continues to improve transparency;
Amendment 6 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Notes, in this regard, that at the end of 2022, the JU had fully committed the maximum EU operational contributions of EUR 966 million for signed grant agreements under the that programme; notes, ten years after the end of the FP7 programme, around EUR 44.9 million (or 5 %) still remains to be paid for projects yet to be completed; notes that this gap corresponds to 5 projects carrying out research on antimicrobial resistance (AMR); notes, furthermore, that 2 of these projects completed their activities by the end of 2022; acknowledges that AMR is a challenging field of research and appreciates the scientific and societal value of funding the development of novel approaches to fight antibiotic resistance;
Amendment 7 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Notes that, for Horizon 2022 activities the JU received no new operational commitment appropriations, as the itProgramme had finished its last call for proposals by the end of 2020; notes that the implementation rate for the operational payment appropriations was at the level of 87% (96% in 2021);
Amendment 8 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14 a. Notes, from the 2022 Corporate Annual Activity Report, that the IHI Joint Undertaking has performed well against the majority of the IMI2 key performance indicators (KPIs), often exceeding the established targets; welcomes, in particular, that the IHI Joint Undertaking’s projects funded under IMI2 have completed 24 regulatory procedures, including two regulatory letters of support, ten regulatory qualified opinions, two submissions for qualification opinion and the inclusion in six regulatory guidelines;
Amendment 9 #
Motion for a resolution
Paragraph 14 b (new)
Paragraph 14 b (new)
14 b. Notes with appreciation that a share of 58.3% (above the 50% target) of the IHI Joint Undertaking’s projects funded under IMI2 have made accessible their resources and outputs beyond the consortia partners; highlights examples such as the library of chemical compounds, the European Compound Collection, established by the ESCulab project, the open source RADAR-base data platform developed by RADAR-CNS, the European federated data network, established by the EHDEN project, or the self-sustaining pluripotent stem cells biobank delivered by EBiSC2;
Amendment 10 #
Motion for a resolution
Paragraph 14 c (new)
Paragraph 14 c (new)
14 c. Welcomes the fact that about 67% of papers produced by the projects funded by the Joint Undertaking have co-authors from different sectors, demonstrating the cross-disciplinary nature of the research and the collaborative approach of its projects;
Amendment 12 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Notes, as regards to gender balance, that and geographical balance, around 65% of staff are women and around 35% are male, coming from 15 different nationalities within IHI Joint Undertaking in 31 December 2022;